|
|
Article: Cepheid Initiates U.S. Shipment of IDI-Strep B(TM) Assay for Detection of Group B Streptococcus in Expectant Women.
- Article from:
- PR Newswire
- Article date:
- April 9, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Cepheid , today announced that it has initiated shipment of the IDI-Strep B(TM) assay for the rapid detection of the presence of Group B Streptococcus (GBS) infection in expectant women. Cepheid will market the assay developed by Cepheid's partner, Infectio Diagnostic (IDI) Inc. in the United States.
According to the American College of Obstetricians and Gynecologists, Group B streptococcus (GBS) is a type of bacteria that can be found in up to 40% of pregnant women. A woman with GBS can pass it on to her fetus when she is pregnant or to her baby during delivery or after birth.
The Centers for Disease Control and Prevention (CDC) incidence data ...